

WHO OFFICE SLOVAKIA
SLOVAK SOCIETY FOR PHARMACOECONOMICS
Slovak Medical Association
SLOVAK CHAMBER OF PHARMACISTS
ISPOR CHAPTER SLOVAKIA
FACULTY OF HEALTHCARE
Alexander Dubček University of Trenčín
SLOVAK SOCIETY OF CLINICAL PHARMACOLOGY
Slovak Medical Association

Scientific conference
(in on-line and live form)

PHARMACOECONOMICS IN SLOVAKIA XLIV.

Health and Drug Policy and Health Care

Pharmacoeconomics and Health Technology Assessment

8th December 2022, Bratislava

Conference room, Ministry of Health

7.45

OPENING

PharmDr. Martin Višňanský, MBA, PhD., MSc.

Slovak Society for Pharmacoeconomics, president

Mgr. Peter Polák, PhD.

Section of Pharmacy and Drug Policy, general director, Ministry of Health

8.00 – 12.45

BLOCK I.

Chairman: PharmDr. Dominik Tomek, PhD., MPH, MSc.

Young Pharmacoeconomists Forum (and their potential for Pharmacoeconomics and HTA development)

1. Quality of life of patients with depression in the context of social and economic aspects of public health
Erika Šipošová, Slovak Society for Pharmacoeconomics, Bratislava
Ján Bielik, Faculty of Healthcare, Alexander Dubček University of Trenčín, Trenčín
2. Methodological aspects of health technology assessment and their implications in selected the field of health care
Jana Rozmarínová, Masaryk University, Brno, Czech Republic
3. *Evaluation of digital health technologies and their implementation into the system health care*
Kristína Suchánková, Slovak Society for Pharmacoeconomics, Bratislava

Ministry of Health nad NIHO Forum

4. The first assessment of the impact of the amendment to Act 363/2011 on the drug policy of the Slovak Republic
Peter Polák, Ministry of Health, Slovak Republic

5. Evaluation of the first year of activities of the National Institute for Value and Technologies in Health
Michal Staňák, National Institute for Value and Technologies in Health, Slovakia
6. NIHO methodology for economic evaluations of medicines – professional, transparent and predictable for the purpose of favorable value for money for patients and taxpayers
Daniel Kozák, National Institute for Value and Technologies in Health, Slovakia

10.15 – 10.30 REFRESHMENTS

Patient's Forum

7. The way and forms of state investments in the improved life of residents and public health
Elena Marušáková, Mária Lévyová, Association for the Protection of Patients' Rights in the Slovak Republic
8. Do we know how much patients actually pay for drugs?
Dominik Tomek, Association for the Protection of Patients' Rights in the Slovak Republic
Dagmar Hroncová, InovaHealth, Bratislava
Radovan Štetka, Boehringer Ingelheim RCV GmbH & Co KG, o.z., Bratislava

Health Insurers Companies Forum

9. Modeling the cost-effectiveness of incoming oncology drugs
Jozef Urbín, General Health Insurance Company, JSC

10. Innovative and rational pharmacotherapy as a criterion for rewarding providers of health care?
Roman Mužik, Beáta Saal, Martin Selvek, Dôvera (Trust) Health Insurance Company, JSC
11. Budget 2023 for the health sector
Martin Smatana, General Health Insurance Company, JSC

Slovak Society for Pharmacoeconomics and ISPOR Chapter Slovakia Forum

12. Telemedicine helps the nurse
Dominik Tomek, Department of Clinical Pharmacology, Faculty of Medicine SZU, Bratislava
Simona Házová, Oncological Institute of St. Elizabeth, Bratislava
13. Evaluation of the quality of life and socio-economic situation of patients with hereditary angioedema in Slovakia
Martin Suchanský, Martina Ondrušová, Miloš Jeseňák
Pharm-In, Bratislava, ISPOR Chapter Slovakia,
Department of Clinical Immunology and Allergology, Martin University Hospital, Martin
14. Personalized medicine: Slovakia versus world
Jana Terifajová, Slovak Society for Pharmacoeconomics
15. Applied Health Economics & CEHETAR / SHERLOCK Project - capacity building for development of applied health economics at Masaryk University in Brno
Dominik Grega, Jakub Hlávka, Jana Soukupová, Martin Višňanský
Masaryk University, Brno, Czech Republic

12.45 – 13.15 REFRESHMENTS, LUNCH

13.15 – 15.30

BLOCK II.

Chairman: PharmDr. Dominik Tomek, PhD., MPH, MSc.

Pharmaceutical Companies Forum

16. The expected impact of the amendment to Act No. 363/2011 on the entry of new medicines. It will do without resources for investment?
Iveta Pálešová, Innovative Pharmaceutical Industry Association (AIFP)
17. The expected impact of the amendment to Act No. 363/2011 on generic and biosimilar medicines
Terézia Szádočka, Association for Generic and Biosimilar Medicines (GENAS)
18. Innovative treatment and its impact on increasing therapeutic goals
Marta Hájková, Clinic of Pneumology and Phthysiology I., Slovak Health University and University Hospital Bratislava

Digital and robotic health technologies in hospital and ambulatory health care

19. Pilot testing of digital health technologies in Hospital
Peter Glatz, Hospital Prievidza, Prievidza-Bojnice
20. The medication process and the central drug preparation room at the Bory Hospital
Ľuboš Doršic, Hospital Bory, Bratislava

21. Healthcare digitizing in Scotland

Andrea Pavlickova

*International Engagement Manager, Technology Enabled Care
and Digital Healthcare*

Innovation, NSS National Services Scotland, Scotland

15.45

CONCLUSION

doc. MUDr. Ján Bielik, CSc.,

Slovak Society for Pharmacoeconomics, CSO SMA

The Accreditation Council of Slovakia for Continuing Medical Education as well as the Slovak Pharmaceutical Chamber granted the event by **7 credits**. Attendance at the conference is free.

The conference will be held in on-line and „live“ form.

Full-time and distance form will be possible for lecturers.

Registration for the conference is only possible online via <https://fz.tnuni.sk/index.php?id=231> and so **from 1.11.2022 till 6.12.2023**.

KAMEAT, s.r.o. participates on organization and TAJPAN, s.r.o. participate on technical assurance of the conference.

You can follow any changes in the program as well as information about the conference at www.fz.tnuni.sk

Scientific committee

Chairman: doc. MUDr. Ján Bielik, CSc.

Members: prof. RNDr. Viliam Foltán, CSc., prof. MUDr. Jozef Holomáň, CSc., MUDr. Darina Sedláková, MPH, PharmDr. Martin Višňanský, MBA, PhD., MSc., PharmDr. Dominik Tomek, MPH, PhD, RNDr. Mária Bucek Pšenková, MPH, MUDr. Elena Marušáková, MBA, PhD, PhDr. Iveta Matišáková, PhD, PhDr. Katarína Gerlichová, PhD, RNDr. Zdenka Krajčovičová, PhD

Organizational committee

Chairman: doc. MUDr. Ján Bielik, CSc.

Members: Ing. Terézia Čögleyová, Ing. Veronika Dvoráková, PhDr. Pavel Grabczak, PhD

PHARMACOECONOMICS IN SLOVAKIA XLIV.